The honest answer by insurance type — commercial, Medicare, Medicaid, employer — and what to do when coverage is denied
Insurance coverage for weight loss injections is one of the most confusing and frustrating aspects of accessing these medications. The answer varies dramatically depending on your specific insurance plan, your diagnosis, which medication is prescribed, and which state you live in.
Here’s the complete, honest guide — by insurance type, with practical strategies for maximizing your chances of coverage.
The Short Answer by Insurance Type
Commercial insurance (employer-sponsored or individual marketplace): Coverage varies widely — some plans cover it, many don’t. Improving but still inconsistent.
Medicare Part D: Currently does NOT cover weight loss medications — a significant coverage gap affecting millions of older Americans. Legislative change is being pursued.
Medicaid: Varies by state — some states cover, most don’t. Expanding slowly.
VA (Veterans Affairs): Coverage varies — some veterans can access through VA formulary.
TRICARE (military): Limited coverage — primarily for active duty with specific criteria.
Commercial Insurance — The Most Variable Landscape
What Affects Commercial Coverage
Commercial insurance coverage for weight loss injections depends on:
Your specific plan: Even within the same employer or insurer, different plan tiers have different formularies. A premium plan may cover what a basic plan doesn’t.
The indication:
- Diabetes indication (Ozempic/Mounjaro): Much better coverage — most plans covering diabetes medications include these
- Weight loss indication (Wegovy/Zepbound): Inconsistent — many plans explicitly exclude weight loss medications
Your employer’s decisions: Self-insured employers (most large companies) design their own benefit structures. Some have explicitly added GLP-1 coverage; others have explicitly excluded it.
Your state: Some states mandate weight loss medication coverage or have specific Medicaid expansions.
How to Check Your Commercial Coverage
Step 1: Read your Summary of Benefits and Coverage (SBC) Available through your employer’s benefits portal or insurance company website. Search for “obesity,” “weight management,” or specific drug names.
Step 2: Check the formulary Your plan’s drug formulary lists covered medications and their tier. Access through your insurance company’s website — search by drug name (Wegovy, Zepbound, Ozempic, Mounjaro).
Step 3: Call member services directly Most reliable method — call the number on your insurance card and ask:
- “Is Wegovy (semaglutide 2.4mg) covered under my plan for weight management?”
- “Is Zepbound (tirzepatide) covered under my plan?”
- “What are the prior authorization requirements?”
- “What is my copay/coinsurance after meeting deductible?”
Step 4: Ask your prescriber Your doctor’s office typically has staff who handle prior authorization and know which plans tend to cover these medications.
Prior Authorization — What’s Required
Even when covered, prior authorization is almost universally required for weight loss medications. Prior authorization typically requires documentation of:
BMI criteria:
- BMI ≥ 30, OR
- BMI ≥ 27 with at least one qualifying condition
Qualifying conditions (varies by plan):
- Type 2 diabetes or prediabetes
- Hypertension
- Dyslipidemia (high cholesterol/triglycerides)
- Obstructive sleep apnea
- Cardiovascular disease
- Sometimes: PCOS, osteoarthritis, NASH/NAFLD
Previous weight loss attempts: Many plans require documentation of previous attempts at medically supervised weight loss through diet and exercise — typically 3-6 months.
Medical necessity letter: Your prescriber writes a letter documenting why the medication is medically necessary for your specific situation.
Step therapy requirements: Some plans require trying and failing other weight loss medications before approving GLP-1 medications — even if older medications (orlistat, phentermine) are less effective.
When Coverage Is Denied
Step 1: Request a denial letter The insurer must provide written explanation of why coverage was denied.
Step 2: File an internal appeal You have the right to appeal. Your prescriber should provide additional documentation supporting medical necessity. Include:
- Clinical evidence supporting GLP-1 use
- Your complete medical history and comorbidities
- Peer-reviewed literature on medication efficacy
- Documentation of previous weight loss attempts
Step 3: Request external review If internal appeal fails, you can request independent external review — a third party reviews the denial independently of the insurer.
Step 4: State insurance commissioner complaint If you believe the denial violates state insurance law, file a complaint with your state’s insurance commissioner.
Step 5: Alternative access while appealing Use manufacturer savings programs or telehealth compounded options while navigating the appeals process.
Medicare — The Most Significant Coverage Gap
The Current Situation
Medicare Part D currently does not cover weight loss medications — a legal prohibition that has existed since 2003 under the Medicare Modernization Act, which explicitly excluded “agents for anorexia, weight loss, or weight gain” from Part D coverage.
This prohibition affects:
- Approximately 67 million Medicare beneficiaries
- Disproportionately impacts older adults with obesity — a population with the highest cardiovascular risk that would benefit most from semaglutide’s documented 20% cardiovascular event reduction
The one exception: Medicare does cover GLP-1 medications for the diabetes indication — Ozempic and Mounjaro are covered by most Part D plans when prescribed for type 2 diabetes management.
What this means practically:
- Medicare beneficiaries with type 2 diabetes can access semaglutide/tirzepatide through their diabetes prescription at standard Part D copays
- Medicare beneficiaries without diabetes cannot access brand name weight loss medications through Medicare at all
- These patients typically access through compounded telehealth options at out-of-pocket cost
The Legislative Situation
The Treat and Reduce Obesity Act (TROA) has been introduced in Congress multiple times — proposing to remove the Medicare weight loss medication exclusion. As of the time of writing, it has not passed — but the political momentum is increasing as the evidence for these medications’ cardiovascular and metabolic benefits accumulates.
The SELECT trial finding — that semaglutide reduces cardiovascular events by 20% — has significantly strengthened the political case for Medicare coverage, as cardiovascular disease is the primary health burden of the Medicare population.
Watch for legislative developments — Medicare coverage, if it passes, would dramatically change the access landscape.
Medicare Advantage (Part C)
Some Medicare Advantage plans offer additional benefits beyond traditional Medicare — a small number have added weight loss medication coverage as an extra benefit. Check your specific Medicare Advantage plan’s formulary.
Medicaid — State-by-State Variation
Medicaid coverage for weight loss medications varies by state — from no coverage to relatively comprehensive coverage.
States with more comprehensive coverage: A small number of states have expanded Medicaid coverage to include weight loss medications:
- Some have added GLP-1 medications to their formulary for obesity
- Others cover only for specific comorbidities (diabetes, cardiovascular disease)
Most states: Limited or no Medicaid coverage for weight loss medications specifically. Diabetes indication coverage follows standard Medicaid formulary for diabetes medications.
How to check your state’s Medicaid coverage:
- Contact your Medicaid managed care plan directly
- Ask specifically about semaglutide and tirzepatide
- Check your state’s Medicaid formulary online
The Medicaid expansion trend: As clinical evidence accumulates — particularly the cardiovascular outcomes data — more states are evaluating Medicaid coverage expansion for weight loss medications. This is an evolving area.
Employer-Sponsored Insurance — The Most Promising Landscape
Large self-insured employers have been the fastest-moving sector in GLP-1 coverage — both adding and removing coverage as they assess cost and clinical value.
Employers Adding Coverage
A growing number of large employers have added explicit GLP-1 medication coverage:
- Some with BMI-only criteria (no additional conditions required)
- Some with BMI + comorbidity requirements
- Some with lifestyle program requirements alongside medication
Why employers are adding coverage:
- Productivity gains from healthier workforce
- Reduction in downstream healthcare costs (diabetes, cardiovascular disease, joint replacement)
- Employee retention and recruitment benefit
- Growing clinical evidence of cost-effectiveness
Employers Removing or Limiting Coverage
The cost of GLP-1 medications at scale has caused some employers to reverse coverage decisions:
- Some have added BMI caps (covering only BMI ≥ 35 or 40)
- Some have added lifestyle program requirements
- Some have capped the benefit duration
- A few large employers have removed coverage entirely after cost analysis
How to Maximize Employer Coverage
Ask HR directly: “Does our health plan cover Wegovy or Zepbound for weight management? What are the requirements?”
Check at benefits enrollment: Annual open enrollment is when coverage changes — review the formulary and benefits summary carefully each year.
Advocate for coverage: Some HR departments are unaware of employee interest in weight loss medication coverage. Employees who express interest — professionally and in aggregate — can influence benefits decisions.
Check all plan options: If your employer offers multiple plan tiers, check each one’s formulary — the premium plan may cover what the standard plan doesn’t.
The HSA/FSA Strategy — Works Regardless of Insurance
Regardless of whether insurance covers weight loss injections, Health Savings Accounts and Flexible Spending Accounts provide a tax-advantaged way to pay:
The benefit: Pre-tax dollars reduce the effective cost by your marginal tax rate:
- 22% bracket: $300/month costs $234 in pre-tax dollars
- 24% bracket: $300/month costs $228 in pre-tax dollars
- Annual savings on $300/month: $864-$864 at 22-24% brackets
HSA contribution limits (2026):
- Individual: $4,300/year
- Family: $8,550/year
FSA contribution limits:
- Typically $2,850-3,050/year (employer-set)
For someone on compounded medication at $250/month ($3,000/year), HSA funds can cover the entire annual cost tax-advantaged.
The Manufacturer Savings Card Strategy
For commercially insured patients (not Medicare/Medicaid) — manufacturer savings cards can dramatically reduce out-of-pocket cost even when the medication is “covered” at a high tier or “not covered” but accessible at cash price:
Novo Nordisk (Wegovy/Ozempic):
- Eligible commercially insured patients: as low as $0-25/month
- Available at: novonordisk-us.com
- Time-limited: typically 12-24 months of eligibility
Eli Lilly (Zepbound/Mounjaro):
- Eligible commercially insured patients: as low as $25-50/month
- Available at: zepbound.com/savings or lillyinsulinvalue.com
The critical eligibility requirement: These savings cards explicitly exclude Medicare and Medicaid beneficiaries — federal law prohibits pharmaceutical companies from offering discounts to government program patients.
Prior Authorization Tips That Actually Work
If you’re pursuing insurance coverage, these strategies improve approval odds:
Document everything: Every weight-related health condition, every previous weight loss attempt, every medication tried. The more documented medical necessity, the stronger the case.
Frame around comorbidities: Insurance is more likely to cover when the prescription is framed around comorbidity management (diabetes prevention, cardiovascular risk reduction, sleep apnea treatment) rather than cosmetic weight loss.
Use the SELECT trial: For patients with cardiovascular risk factors, the SELECT trial’s 20% reduction in major cardiovascular events is compelling clinical evidence. Your prescriber’s letter should reference this data.
Reference the medical necessity: Letters that cite peer-reviewed literature and specific guideline recommendations (American Heart Association, Endocrine Society, AACE) carry more weight than generic medical necessity statements.
Ask for peer-to-peer review: If coverage is denied, request that your doctor speak directly with the insurance company’s medical director — peer-to-peer conversations resolve more denials than paper appeals.
File appeals promptly: Appeals have time limits — typically 30-180 days from denial. File promptly even before fully preparing your case.
The Telehealth + Compounded Option — Regardless of Insurance
For people who can’t navigate insurance successfully or who need access faster than the approval process allows:
Compounded semaglutide and tirzepatide through licensed telehealth providers provide effective medication at $150-500/month — without insurance dependency.
As covered in our guide to how to afford weight loss injections without insurance, this pathway provides access for most people regardless of insurance situation.
Gala offers telehealth evaluation and access to compounded GLP-1 medications — with medical oversight throughout treatment and pricing that doesn’t depend on insurance approval.
[Check eligibility and pricing at Gala →]
This is a paid partnership. Gala is a licensed telehealth provider. Medication is only prescribed following a medical consultation and is not guaranteed.
Quick Reference: Coverage by Insurance Type
| Insurance Type | Weight Loss Coverage | Diabetes Coverage | Notes |
|---|---|---|---|
| Commercial (employer) | Inconsistent | Usually yes | Check specific plan |
| Commercial (marketplace) | Inconsistent | Usually yes | Check specific plan |
| Medicare Part D | No | Yes | Legislative change pending |
| Medicare Advantage | Rarely | Usually yes | Check specific plan |
| Medicaid | Varies by state | Usually yes | Check your state |
| VA | Varies | Usually yes | Check VA formulary |
| TRICARE | Limited | Usually yes | Active duty criteria |
| No insurance | N/A | N/A | Compounded telehealth $150-500/month |
The Bottom Line
Does insurance cover weight loss injections?
It depends — and the answer is changing:
- Commercial insurance: Increasingly likely, but not guaranteed. Check your specific plan, pursue prior authorization with documentation, appeal denials.
- Medicare: No for weight loss indication — yes for diabetes indication. Legislative change being pursued.
- Medicaid: Usually no, state-dependent, slowly expanding.
- No insurance: Compounded telehealth options at $150-500/month are the most accessible alternative.
The practical roadmap:
- Check your specific plan formulary
- If covered: pursue prior authorization with full comorbidity documentation
- If commercially insured: get manufacturer savings card regardless
- If denied: appeal with peer-reviewed evidence and peer-to-peer review request
- If Medicare/Medicaid or no insurance: compounded telehealth is the most accessible pathway
For the complete picture, see our guides to how much weight loss injections cost and how to afford weight loss injections without insurance.
Have you navigated insurance coverage for weight loss injections — and what strategies worked for getting approval? Share in the comments.
